October 15, 2014

What’s in a name? A lot, apparently, if the name applies to a biosimilar medicine.

October 14, 2014

U.S. Sen. Bernie Sanders, I-Vt., and U.S. Rep. Elijah Cummings, D-Md., earlier this month launched an investigation into soaring generic drug prices.

October 14, 2014

Following the completion of a joint venture between GlaxoSmithKline and Novartis' consumer health units, Brian McNamara, currently division head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses.

October 10, 2014

New patient research commissioned by McKesson Patient Relationship Solutions identified emerging trends in medication adherence, the use of co-pay cards, and attitudes towards healthcare providers, including both physicians and pharmacists.

October 8, 2014

Pending legislation in the Pennsylvania state legislature is raising the eyebrows of several industry members, including the National Community Pharmacists Association, which stated that the legislation in its current form would "severely limit access to more affordable medications, vastly increase overall healthcare costs to Pennsylvania businesses and citizens and add cumbersome reporting requirements on healthcare providers."

October 8, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday released a new report highlighting the number of investigational cancer medicines that did not succeed in clinical trials. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

October 7, 2014

America’s biopharmaceutical research companies are currently developing nearly 800 new medicines and vaccines for cancer, according to a new PhRMA report.


September 29, 2014

According to a report released Monday by Thomson Reuters BioWorld, currently there are 700 follow-on biologics therapies moving through pipelines with many already approved.

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

September 24, 2014

In honor of the 30th anniversary of the Drug Price Competition and Patent Term Restoration Act — more commonly known as the Hatch Waxman Act — which enabled manufacturers to bring generic versions of pharmaceuticals to market more easily, GPHA president Ralph Neas issued a statement.

September 24, 2014

In celebration of the 30th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act, also known as the “Hatch-Waxman” Act, the National Association of Chain Drug Stores issued a statement to reflect on the evolution of providing patient access to generic medications and noted that it is looking forward to further progress in the years ahead.

September 23, 2014

A bill has been introduced that lawmakers say would “close federal loopholes” and increase consumer access to generic drugs while boosting market competition.

September 18, 2014

The Generic Pharmaceutical Association on Thursday provided input on the Generic Drug User Fee Act process before the Food and Drug Administration. 

September 10, 2014

The Generic Pharmaceutical Association on Wednesday released a report showing that generic drugs saved the United States health system $239 billion in 2013.

September 2, 2014

More than 55% of people suffer from swallowing difficulties when taking tablets or capsules, which is likely to inhibit compliance, according to an international survey conducted by Spiegel Institute Mannheim on behalf of Hermes Pharma. 

August 27, 2014

The International Society for Pharmaceutical Engineering on Wednesday announced that it has released a preview of its Drug Shortages Prevention Plan aimed at helping the pharmaceutical industry avoid drug shortages and maintain a reliable supply of medications. 

August 25, 2014

Biotech company Roche will be acquiring research and pharmaceutical company InterMune for $8.3 billion, it announced over the weekend. 

August 21, 2014

The generic drug industry — and by extension, patients across the United States — is being adversely impacted by what some are calling branded drug makers’ abuse of risk evaluation and mitigation strategies, or REMS.

August 21, 2014

Restricting access to samples of generic biological drugs would lead to nearly $140 million in lost savings for every $1 billion in biologics sales, Matrix Global Advisors said.

August 20, 2014

Despite creating a detailed plan to speed up the rate at which generic drug applications are reviewed, experts say a backlog has developed at the Food and Drug Administration’s Office of Generic Drugs.

August 20, 2014

Excedrin relaunched in the United States in 2013 and is doing well. The brand generated $130 million between its Excedrin tablets and Excedrin Migraine tablets for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.

August 19, 2014

"The consumer healthcare market has experienced a steady stream of mergers and acquisitions in recent years. Some of this has created small ripples — like pebbles being gently tossed into still waters. Then there are the mega-mergers that have had a tsunami-like effect," writes Dave Wendland, Hamacher Resource Group VP, in his latest blog entry.

August 18, 2014

The Food and Drug Administration will be hosting an all-day hearing on Sept. 17 seeking public comment on five draft guidance documents related to the implementation of the Generic Drug User Fee Amendments of 2012, as well as input on future policy priorities.